Jiangxi Fushine Pharmaceutical Co Ltd Tangible Net Worth Ratio
Jiangxi Fushine Pharmaceutical Co Ltd tangible net worth ratio. Jiangxi Fushine Pharmaceutical Co Ltd (300497) has a Tangible Net Worth Ratio of 87.5% as of June 2026. This metric is calculated by deducting intangible assets (CN¥298.43 Million) from net assets (CN¥2.38 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Jiangxi Fushine Pharmaceutical Co Ltd (300497) equity growth momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
Tangible net worth ratio of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025. This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's Tangible Net Worth Ratio has changed across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 87.5%, reflecting net assets of CN¥2.38 Billion with intangible assets of CN¥298.43 Million CNY. Check 300497 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Jiangxi Fushine Pharmaceutical Co Ltd Tangible Net Worth Ratio by Year (2011–2025)
Jiangxi Fushine Pharmaceutical Co Ltd tangible net worth ratio by year from 2011 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 300497 market cap overview.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 86.9% | CN¥2.20 Billion | CN¥287.85 Million | CN¥4.40 Billion | ▼ -2.3 pp |
| 2024 | 89.2% | CN¥2.18 Billion | CN¥235.00 Million | CN¥4.54 Billion | ▼ -1.0 pp |
| 2023 | 90.2% | CN¥2.47 Billion | CN¥241.07 Million | CN¥4.82 Billion | ▼ -0.5 pp |
| 2022 | 90.7% | CN¥2.69 Billion | CN¥249.71 Million | CN¥5.06 Billion | ▼ -0.5 pp |
| 2021 | 91.2% | CN¥2.91 Billion | CN¥256.32 Million | CN¥4.68 Billion | ▼ -0.7 pp |
| 2020 | 91.9% | CN¥3.05 Billion | CN¥246.28 Million | CN¥4.05 Billion | ▼ -0.5 pp |
| 2019 | 92.4% | CN¥1.53 Billion | CN¥116.51 Million | CN¥2.60 Billion | ▲ +1.3 pp |
| 2018 | 91.1% | CN¥1.15 Billion | CN¥102.58 Million | CN¥2.20 Billion | ▲ +2.2 pp |
| 2017 | 88.9% | CN¥966.71 Million | CN¥107.75 Million | CN¥1.79 Billion | ▼ -0.5 pp |
| 2016 | 89.3% | CN¥784.17 Million | CN¥83.80 Million | CN¥1.40 Billion | ▼ -0.5 pp |
| 2015 | 89.8% | CN¥596.21 Million | CN¥60.85 Million | CN¥1.01 Billion | ▲ +11.6 pp |
| 2014 | 78.2% | CN¥283.26 Million | CN¥61.87 Million | CN¥632.35 Million | ▲ +5.7 pp |
| 2013 | 72.5% | CN¥229.76 Million | CN¥63.27 Million | CN¥541.31 Million | ▲ +7.5 pp |
| 2012 | 65.0% | CN¥184.60 Million | CN¥64.62 Million | CN¥476.31 Million | ▲ +16.2 pp |
| 2011 | 48.8% | CN¥120.52 Million | CN¥61.67 Million | CN¥352.57 Million | — |